secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001558370-23-004930
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio reports FY2022 net loss $77.5M; MB-106 shows 96% ORR, 75% CR
------------------------------------------------------------------------

- Cash and equivalents $76.7M at Dec 31, 2022, down from $110.6M year-over-year.
- Net loss $77.5M ($0.75/share) vs $66.4M ($0.76/share) in 2021; R&D expenses rose to $62.5M.
- MB-106 CAR T therapy achieved 96% ORR and 75% CR in hematologic malignancies; FDA Orphan Drug Designation for Waldenstrom macroglobulinemia.
- Completed $75M debt financing with Runway Growth Capital; $30M funded at close, $45M milestone-based.
- Plans to treat first pivotal Phase 2 WM patient in Q1 2024; additional data expected in Q2 and Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023004930/0001558370-23-004930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023004930/tmb-20230329x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-004930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer